Option Care Health (NASDAQ:OPCH – Get Free Report) updated its FY 2024 earnings guidance on Monday. The company provided earnings per share guidance of 1.550-1.590 for the period, compared to the consensus earnings per share estimate of 1.210. The company issued revenue guidance of $5.0 billion-$5.0 billion, compared to the consensus revenue estimate of $4.9 billion. Option Care Health also updated its FY 2025 guidance to 1.590-1.690 EPS.
Wall Street Analysts Forecast Growth
OPCH has been the topic of a number of recent research reports. Barrington Research boosted their price target on shares of Option Care Health from $32.00 to $33.00 and gave the stock an “outperform” rating in a research note on Tuesday. The Goldman Sachs Group cut Option Care Health from a “buy” rating to a “neutral” rating and cut their price target for the company from $38.00 to $27.00 in a research note on Monday, November 4th. UBS Group initiated coverage on shares of Option Care Health in a report on Thursday, December 5th. They issued a “neutral” rating and a $26.00 target price for the company. Jefferies Financial Group downgraded Option Care Health from a “buy” rating to a “hold” rating and dropped their price target for the stock from $38.00 to $26.00 in a research note on Thursday, October 31st. Finally, Bank of America raised shares of Option Care Health from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $26.00 to $33.00 in a research report on Monday. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.86.
Check Out Our Latest Analysis on OPCH
Option Care Health Stock Performance
Insiders Place Their Bets
In other news, Director Harry M. Jansen Kraemer, Jr. acquired 43,000 shares of Option Care Health stock in a transaction that occurred on Friday, November 8th. The stock was purchased at an average cost of $22.54 per share, with a total value of $969,220.00. Following the completion of the acquisition, the director now owns 326,334 shares in the company, valued at $7,355,568.36. This trade represents a 15.18 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.64% of the company’s stock.
About Option Care Health
Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.
See Also
- Five stocks we like better than Option Care Health
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- AAR Corp Jets Higher on Robust Demand for Aircraft Components
- What is Insider Trading? What You Can Learn from Insider Trading
- Everything You Need to Know About Palantir’s Stock Slide
- Upcoming IPO Stock Lockup Period, Explained
- Why Nike Is on The Verge of a Massive Comeback Rally
Receive News & Ratings for Option Care Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Option Care Health and related companies with MarketBeat.com's FREE daily email newsletter.